RESTEM to Showcase Innovative Cell Therapies at Jones Las Vegas Technology Conference

RESTEM, a Miami-based clinical-stage biotechnology company, is set to participate in the Jones Las Vegas Technology and Innovation Conference, offering investors and industry professionals insights into its cutting-edge cell therapy development strategies. The company's Chief Executive Officer, Andres Isaias, will deliver a virtual corporate overview on Wednesday, April 9, 2025, at 11:00 a.m. Pacific Time.

The conference represents a critical platform for innovative biotechnology companies to engage with institutional investors and showcase emerging medical technologies. By participating in this event, RESTEM aims to highlight its advanced research in developing off-the-shelf cell therapies designed to modulate the immune system and address complex medical challenges.

RESTEM's research focuses on two promising therapeutic programs: Restem-L, an umbilical cord lining stem cells (ULSCs) program targeting autoimmune diseases, and a natural killer cell (NK) therapeutic approach addressing senescence and age-associated disorders. These innovative therapies represent potential breakthroughs in treating previously challenging medical conditions.

The company's approach leverages proprietary products, robust clinical development expertise, and advanced manufacturing capabilities. By developing therapies intended to improve patient outcomes and overall health, RESTEM is positioning itself at the forefront of regenerative medicine and immunological treatment strategies.

The Jones Las Vegas Technology and Innovation Conference will provide a unique opportunity for RESTEM to engage with potential investors, showcase its technological advancements, and demonstrate the transformative potential of its cell therapy research. The event's focus on one-on-one meetings, fireside chats, and panels creates an ideal environment for in-depth discussions about the company's scientific and commercial potential.

Investors and industry professionals interested in the presentation can access a live webcast, with a replay available on RESTEM's corporate website following the event. This accessibility underscores the company's commitment to transparency and broad engagement with the scientific and investment communities.

RESTEM's participation in this conference signals the company's continued momentum in developing innovative cell therapies that could potentially revolutionize treatment approaches for autoimmune and age-related disorders. By focusing on next-generation cellular technologies, the company represents a critical node of innovation in the biotechnology sector.